[e-drug] Post trial access to treatment

e-drug
1

E-DRUG: Post trial access to treatment
----------------------------------------------------------------------------

Dear reader,

I would like to draw your attention to SOMO's latest research
'Post-trial access to treatment. Corporate best practices' This
research gives an overview of corporate best practices related to the
provision of Post-Trial Access to Treatment (PTA) in low and middle
income countries (LMICs. The paper 'Post-Trial Access To Treatment' gives
an overview of corporate best practices related to the provision of
Post-Trial Access to Treatment (PTA) in low and middle income countries
(LMICs). SOMO analysed the policies of the biggest pharmaceutical on
PTA, analysed the strong elements regarding PTA in international ethical
guidelines, and reviewed the academic debate on this topic. The aim of
this paper is to fill the knowledge gap about how the pharmaceutical
industry currently deals with PTA in practice and to contribute to a
high yet realistic standard of PTA in low- and middle-income countries
(LMICs).

You can find more information on
http://somo.nu/1EJoHTT

About SOMO
The Centre for Research on Multinational Corporations (SOMO) is an
independent, not-for-profit research and network organisation working on
social, ecological and economic issues related to sustainable
development. Since 1973, the organisation investigates multinational
corporations and the consequences of their activities for people and the
environment around the world, including the pharmaceutical industry.

Meike Skolnik
Stichting Onderzoek Multinationale Ondernemingen
Centre for Research on Multinational Corporations
Sarphatistraat 30
1018 GL Amsterdam
T: +31 (0)20 6391291
<http://www.somo.nl/&gt;
M.Skolnik@somo.nl